XTSXVM
Market cap8mUSD
Dec 24, Last price
0.09CAD
1D
-5.26%
1Q
50.00%
IPO
-10.00%
Name
Voyageur Pharmaceuticals Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
22.39%
Rev. gr., 5y
%
Revenues
0k
Net income
-1m
L-20.21%
CFO
-991k
L-42.33%
Profile
Voyageur Pharmaceuticals Ltd. focuses on the development of active pharmaceutical ingredients minerals. The company intends to develop barium and iodine radiocontrast products and bromine based pharmaceutical products. It holds 100% interest in three barium sulfate deposits, including two properties suitable in grade for the pharmaceutical barite marketplace located in British Columbia, Canada; and interests in a high-grade iodine, lithium, and bromine brine project in Utah, the United States. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is headquartered in Calgary, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑11 | 2022‑11 | 2021‑11 | 2020‑11 | 2019‑11 | 2018‑11 | 2017‑11 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 659 | 1,752 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (659) | (1,752) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | 2 | |||||||||
Tax Rate | ||||||||||
NOPAT | (659) | (1,754) | ||||||||
Net income | (1,399) -20.21% | (1,754) -14.51% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 1,200 | 1,157 | ||||||||
BB yield | -22.99% | -15.33% | ||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | 40 | 26 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 14 | 14 | ||||||||
Net debt | 24 | (20) | ||||||||
| Cash flow | ||||||||||
Cash from operating activities | (991) | (1,719) | ||||||||
CAPEX | (283) | |||||||||
Cash from investing activities | (175) | (274) | ||||||||
Cash from financing activities | 1,136 | 1,211 | ||||||||
FCF | (609) | (1,578) | ||||||||
| Balance | ||||||||||
Cash | 2 | 32 | ||||||||
Long term investments | 14 | 14 | ||||||||
Excess cash | 16 | 46 | ||||||||
Stockholders' equity | (426) | (177) | ||||||||
Invested Capital | 1,916 | 1,681 | ||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 130,504 | 107,826 | ||||||||
Price | 0.04 -42.86% | 0.07 -22.22% | ||||||||
Market cap | 5,220 -30.84% | 7,548 -11.42% | ||||||||
EV | 5,244 | 7,528 | ||||||||
EBITDA | (657) | (1,743) | ||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||